Successful TiGenix IPO prompts early closing

Leuven (BELGIUM) - March 21, 2007 - TiGenix, the biomedical company focused on innovative local treatments for damaged and osteoarthritic joints, today confirms an early closing of the public offer to subscribe to its capital increase.

Pursuant to the offering, 8,000,000 new shares will be issued by TiGenix equivalent to € 40 million. The final offering price amounts to € 5.00 per share. Shares will start trading as of 22 March 2007 on the Eurolist by Euronext Brussels under the symbol TIG.

More info on TiGenix' website or on the press release